Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2007-06-19
2007-06-19
Parkin, Jeffrey S. (Department: 1648)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
C424S188100, C424S208100
Reexamination Certificate
active
10323463
ABSTRACT:
The present invention provides isolated cells that comprise, integrated into the genome of the cell, a transcription-competent immunodeficiency virus or a transcription-competent immunodeficiency virus-based retroviral vector. Under basal in vitro culture conditions, the immunodeficiency virus is latent, and the expression of the latent immunodeficiency virus can be reactivated. The invention further provides methods of making a subject cell. The invention further provides screening methods for identifying agents that activate a latent immunodeficiency virus; and screening method for identifying agents that block reactivation of latent immunodeficiency virus expression in response to T cell activation signals. The invention further provides agents identified in the subject screening assays. The invention further provides methods of treating an immunodeficiency virus infection.
REFERENCES:
patent: 5256534 (1993-10-01), Butera et al.
patent: 5459056 (1995-10-01), Powell et al.
patent: 6225048 (2001-05-01), Soderberg-Naucler et al.
Chen, B. K., et al., 1994, Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses, J. Virol. 68(2):654-660.
Lewinski et al., “Genome-Wide Analysis of Chromosomal Features Repressing Human Immunodeficiency Virus Transcription”, Journal of Virology, 2005, vol. 79, No. 11, pp. 6610-6619.
Valerie K et al. “Activation of human immunodeficiency virus type 1 by DNA damage in human cells” Nature 1988, pp. 78-81.
Latham P S et al. “Expression of Human Immunodeficiency Virus Long Terminal Repeat in the Human Promonocyte Cell Line U937 Effect of Endotoxin and Cytokines” Cellular Immunology, vol. 129, No. 2. 1990, pp. 513-518.
Jordan Albert et al. “The site of HIV-1 Integration in the human genome determines basal transcriptional activity and response to Tat transactivation” EMBO (European Molecular Biology Organization) Journal, vol. 20, No. 7, Apr. 2001, pp. 1726-1738.
Chen Benjamin K et al. “Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses” Journal of Virology, The American Society for Microbiology, US, vol. 68, No. 2, Feb. 1994, pp. 654-660.
Van Lint Carine et al. “Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to the histone acetylation” EMBO (European Molecular Biology Organization) Journal, vol. 15, No. 5, 1996, pp. 1112-1120.
Verdin Eric et al. “A new in vitro model for HIV latency” Journal of Human Virology, vol. 5, No. 1, Jan. 2002, p. 60 & 2002 International Meeting of the Institute of Human Virology; Baltimore, Maryland, USA; Sep. 9-13, 2002.
Sylvie Legrand-Poels et al. “Activation of Human Immunodeficiency Virus Type 1 by Oxidative Stress”, Aids Research and Human Retroviruses 1990 vol. 6, No. 12, pp. 1389-1397, abstract, Figure 4, and 1395, col. 1, last paragraph.
Bakri, Y. et al. The Maturation of Dendritic Cells Results in Postintegration Inhibition of HIV-1 Replicon. They Journal of Immunology. 2001 vol. 166, pp. 3780-3788, see abstract, and pp. 3781-2782.
Jordan, A et al. “Hiv Reproducibly Establishes a Latent Infection After Acute Infection of T Cells In Vitro”, The EMBO Journal, 2003, vol. 22, No. 8, pp. 1868-1877.
Kulkosky et al. (2001)Blood, 98:3006-3015.
Emiliani et al. (1996)Proc. Natl. Acad. Sci. USA93:6377-6381.
Emiliani et al. (1998)J. Virol.72:1666-1670.
Antoni et al. (1994)Virol.202:684-694.
Carteau et al. (1998)J. Virol.72:4005-4014.
Jordan Albert
Verdin Eric
Borden Paula A.
Bozicevic Field & Francis LLP
Parkin Jeffrey S.
The Regents of the Universtiy of California
LandOfFree
Cell lines with latent immunodeficiency virus and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell lines with latent immunodeficiency virus and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell lines with latent immunodeficiency virus and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3870789